Valuation: Patrys Limited

Market Cap 15.72M 11.06M 9.87M 9.12M 8.26M 15.47M 1.05B 110M 43.45M 550M 41.48M 40.6M 1.73B P/E 2025
-0.68x
P/E 2026 -4.22x
Enterprise Value 12.36M 8.69M 7.76M 7.17M 6.5M 12.17M 825M 86.29M 34.16M 432M 32.62M 31.93M 1.36B EV / Sales 2025
1.96x
EV / Sales 2026 2,223x
Free-Float
70.71%
Yield 2025 *
-
Yield 2026 -
1 day-3.57%
1 week-6.90%
Current month-12.90%
1 month-18.18%
3 months-27.03%
6 months-6.90%
Current year-3.57%
1 week 0.03
Extreme 0.027
0.03
1 month 0.03
Extreme 0.027
0.03
Current year 0.02
Extreme 0.025
0.05
1 year 0.02
Extreme 0.025
0.05
3 years 0.01
Extreme 0.011987
0.13
5 years 0.01
Extreme 0.011987
0.54
10 years 0.01
Extreme 0.011987
0.91
Manager TitleAgeSince
Chief Executive Officer - 16/02/2026
Chief Operating Officer - 01/06/2012
Corporate Secretary - 10/11/2025
Director TitleAgeSince
Director/Board Member - 17/06/2025
Chairman 64 -
Director/Board Member - 10/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
11/08/23 Expiration

Chief Executive Officer

396,132 0.0193%
11/08/23 Expiration

Chief Executive Officer

3,283 0.0002%
06/12/21 Buy

Chief Executive Officer

1,337,164 0.0675%
Change 5-day change 1-year change 3-year change Capi.($)
-3.57%-6.90%-10.00%-71.87% 11.44M
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+3.11%+10.29%+72.56% 54.89B
+0.57%+4.64%+12.82%+89.79% 53.28B
+0.37%+3.07%+28.23%+51.53% 45.81B
-1.21%+0.95%+20.44%+128.58% 43.46B
-0.37%-1.20%+252.94%+568.54% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+4.55%+37.71%+28.10% 23.76B
Average -0.11%-0.05%+43.82%+99.43% 38.19B
Weighted average by Cap. +0.38%+0.55%+48.17%+122.11%

Financials

2025 2026
Net sales 829K 583K 520K 481K 435K 816K 55.32M 5.78M 2.29M 28.98M 2.19M 2.14M 91.43M 8.98K 6.32K 5.64K 5.21K 4.72K 8.84K 600K 62.73K 24.83K 314K 23.71K 23.21K 992K
Net income -3.01M -2.12M -1.89M -1.75M -1.58M -2.97M -201M -21.04M -8.33M -105M -7.95M -7.78M -333M -3.42M -2.4M -2.14M -1.98M -1.8M -3.36M -228M -23.84M -9.44M -119M -9.01M -8.82M -377M
Net Debt -742K -522K -466K -431K -390K -731K -49.57M -5.18M -2.05M -25.97M -1.96M -1.92M -81.93M -3.36M -2.36M -2.11M -1.95M -1.77M -3.31M -224M -23.46M -9.29M -118M -8.87M -8.68M -371M
Projected Income Statement - Annual - Patrys Limited
Logo Patrys Limited
Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.
Employees
10
Date Price Change Volume
23/10/26 A$0.0270 -3.57% 574,454
22/10/26 A$0.0280 0.00% 7,385
21/10/26 A$0.0280 +3.70% 62,965
20/10/26 A$0.0270 0.00% 108,508
16/10/26 A$0.0270 -6.90% 553,613